UTHR
Is United Therapeutics (UTHR) undervalued?
Based on the Buffett-Fit framework, United Therapeutics (UTHR) currently scores 71/100. Valuation is one of the five pillars that drives that score, the stock trades at a P/E of 19.2x, with an owner-earnings yield of 4.3%. Whether UTHR is undervalued depends on the gap between price and a conservative estimate of intrinsic value, broken down below. Educational only, not investment advice.
Headline multiples. United Therapeutics trades at a trailing P/E of 19.2x, a P/B of 4.19x, and an EV-to-EBIT of 15.2x. None of these in isolation tells you whether the stock is undervalued: a 30x P/E is cheap for a quality compounder and expensive for a cyclical commodity producer. The point is the relationship between price and the underlying business quality on the same scale.
Owner-earnings yield. United Therapeutics's owner-earnings yield (free cash flow / enterprise value) currently sits at 4.3%. This is Buffett's preferred valuation lens because it asks "what does the business actually return to a 100% owner?" rather than accounting earnings that can be inflated by accruals. A yield above the 10-year Treasury plus a 4-5% equity-risk premium is the rough benchmark for "cheap" against a high-quality business.
Earnings yield (1/P/E). The inverted P/E gives an earnings yield of 5.2%, useful as a sanity-check against the owner-earnings yield above. Large gaps between the two usually mean either high stock-based compensation eroding cash earnings (yield gap negative) or aggressive working-capital management inflating cash earnings vs accounting earnings (yield gap positive).
What the framework concludes. Valuation alone doesn't decide whether UTHR is a buy, Buffett's full rule is "a wonderful business at a fair price beats a fair business at a wonderful price." The valuation sub-score in the Buffett-Fit verdict on this page combines the metrics above with the company's underlying compounding rate (ROIC × reinvestment) to produce a single 0-100 number. Read the full verdict to see how it sits alongside moat strength, durability, management, and financial health.
How invest-like measures this
Valuation on invest-like.com is graded against three benchmarks: the owner-earnings yield (Buffett's preferred metric, free cash flow divided by enterprise value), the multiple of intrinsic value (DCF and reverse-DCF), and the price relative to the company's underlying compounding rate.
The score weighs these against the sector's median quality benchmarks: a 20x P/E is cheap for a software compounder and expensive for a cyclical commodity producer, so the sector-relative bonus matters. Educational only, not investment advice.
Il s'agit d'une analyse éducative fondée sur des méthodes d'investissement. Ce n'est ni un conseil ni une recommandation, et elle ne connaît pas ta situation. Fais tes propres recherches avant de décider.
